Combination therapy with docetaxel and radiotherapy may be an effective treatment option for primary cardiac angiosarcoma, achieving disease control at 12 months.
Answers are grounded in this paper and cite their sources.
May support docetaxel-radiotherapy exploration in cardiac angiosarcoma; hypothesis-generating and requires prospective validation before practice change.
A 49-year-old man was admitted for primary cardiac angiosarcoma with a cardiac tamponade. Transthoracic echocardiography and contrast-enhanced computed tomography scan demonstrated a large mass in the right atrium and thickening of the right ventricular wall. 18F-labeled deoxyglucose (FDG) positron emission tomography (PET) scan showed increased FDG uptake in the mediastinum and over the heart. The patient responded to combination therapy with docetaxel and radiotherapy and tolerated the treatment well, except for radiation esophagitis, which required a soft diet and resolved 1 month after treatment. This combination therapy resulted in a minimal response with slight regression in the tumor size, but FDG-PET initially showed an increase in FDG uptake by the tumor that was no longer seen after combination therapy. There is no evidence of progression or metastasis even at 12 months after diagnosis.
No takes yet. Share an insight, caveat, or question.
Nakamura-Horigome et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: